85683762 - MABIMMUNE

Information

• Trademark
• 85683762

• Source

• Serial Number

  85683762

• Registration Number

  4896966

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 3 - Bleaching preparations and other substances for laundry use
  • 5 - Pharmaceutical and veterinary preparations
  • 41 - Education
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  July 22, 2012
  12 years ago

• Registration Date

  February 09, 2016
  8 years ago

• Transaction Date

  September 27, 2022
  2 years ago

• Status Date

  August 19, 2022
  2 years ago

• Published for Opposition Date

  November 24, 2015
  9 years ago

• Location Date

  February 09, 2016
  8 years ago

• Status Code

  710

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  VAGHANI, MAYUR C

• Attorney Name

  Janice Housey

  Law Office Assigned Location Code

  L20

• Owners

  • Mabimmune Diagnostics AG

Case File Statements

• GS0411: Physical examination featuring monoclonal antibodies, namely, physical fitness training services, physical performance monitoring in the nature of physical fitness consultation
• GS0051: Pharmaceutical preparations containing monoclonal antibodies for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; pharmaceutical preparations containing monoclonal antibodies for the treatment of metabolic diseases including diabetes mellitus; veterinary preparations containing monoclonal antibodies for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; veterinary preparations containing monoclonal antibodies for metabolic diseases including diabetes mellitus; tumor suppressing agents containing monoclonal antibodies; preparations containing monoclonal antibodies for treating neurodegenerative diseases; immunogenics, namely, pharmaceutical preparations containing monoclonal antibodies for inducing immune responses for the treatment of oncology indications including lymphomas, sarcomas, carcinomas, leukemias, bacterial infections, parasitic disease; vaccines containing monoclonal antibodies; antibodies containing monoclonal antibodies, namely, for treatment of anti-inflammatory, cardiovascular, oncological, and dermatological indications; active epitopes in the form of a pharmaceutical preparation containing monoclonal antibodies which modulate the biological activity of drug targets in-vivo; synthetic peptides containing monoclonal antibodies for pharmaceutical purposes for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; synthetic peptides for pharmaceutical purposes containing monoclonal antibodies for the treatment of metabolic diseases including diabetes mellitus; sanitary preparations containing monoclonal antibodies for medical purposes; biological preparations for medical purposes containing monoclonal antibodies for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; biological preparations for medical purposes containing monoclonal antibodies for the treatment of metabolic diseases including diabetes mellitus; biocides containing monoclonal antibodies; diagnostic preparations for medical or veterinary purposes containing monoclonal antibodies; sanitary towels containing monoclonal antibodies; dietetic food, namely, pasta, crackers, bread adapted for medical purposes containing monoclonal antibodies; dietetic beverages, namely, tea, vitamin fortified beverages, protein shakes adapted for medical purposes containing monoclonal antibodies; algaecide chemicals containing monoclonal antibodies for swimming pools; biological tissue containing monoclonal antibodies such as bone, skin, blood vessels, cartilage, muscle, teeth, extracellular matrix, and heart valve tissue intended for subsequent implantation; synthetic peptides and polypeptides containing monoclonal antibodies for the treatment of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; synthetic peptides and polypeptides for the treatment of metabolic diseases including diabetes mellitus; chemicals, namely, chemical preparations for pharmaceutical or medical purposes containing monoclonal antibodies, namely, for keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; pharmaceutical preparations, namely, medicated scar-reducing lotions containing monoclonal antibodies; burn relief medication ointments containing monoclonal antibodies; Chemicals, namely, chemical preparations containing monoclonal antibodies for medical kits and tests, namely, diagnostic blood tests, companion diagnostics, and blood tests to determine the efficacy of the treatment strategy including both plasma and serum based assays for metabolic, cardiovascular, oncological, and inflammatory diseases
• GS0031: Skin care preparations containing monoclonal antibodies, namely, chemical peels for skin, anti-aging topical creams, anti-wrinkle topical creams, non-medicated lotions which are indicated specifically for reducing scar formation, topical ointments containing monoclonal antibodies indicated for accelerating the healing process or alleviating the symptoms of burns, namely, non-medicated ointments for the prevention and treatment of sunburn, topical beauty products, namely, cosmetics containing monoclonal antibodies
• GS0011: Chemicals, namely, chemical preparations containing monoclonal antibodies for biological assays; industrial chemicals containing monoclonal antibodies; chemical preparations containing monoclonal antibodies for scientific purposes; chemical preparations containing monoclonal antibodies for use in photography; biological materials, namely, biological tissue and cell cultures containing monoclonal antibodies other than for medical or veterinary purposes, inoculants in the nature of biological microorganisms containing monoclonal antibodies used for biomedical research; biological preparations, namely, biological tissue and cell cultures containing monoclonal antibodies other than for medical or veterinary purposes, inoculants containing monoclonal antibodies in the nature of biological microorganisms used for biomedical research; peptides for chemicals and foodstuff, namely, peptide substrates containing monoclonal antibodies used in analyzing and detecting certain biomarkers for laboratory or research use; polypeptides, namely, peptide substrates containing monoclonal antibodies used in analyzing and detecting certain biomarkers for laboratory or research use, protein antibodies, namely, monoclonal antibodies containing monoclonal antibodies for in vitro or in-vivo scientific or research use, antibody reagents containing monoclonal antibodies used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; diagnostic preparations containing monoclonal antibodies for scientific use; Biological compounds, namely, epitopes containing monoclonal antibodies in the nature of enzyme or mis-folded proteins for use in the pre-clinical research and development of pharmaceutical preparations such as antibodies or active peptides
• GS0441: Medical services featuring monoclonal antibodies; medical services featuring monoclonal antibodies in the field of immunity, cardiology, rheumatology, oncology, pneumology, neurology; providing medical information featuring monoclonal antibodies; medical services, namely, conducting physical medical examinations featuring monoclonal antibodies in the fields of keloid scar formation, dermal burns, lymphomas, sarcomas, carcinomas, and leukemias, inflammatory disease, cardiovascular disease, atherosclerosis, rheumatoid arthritis, stroke or an acute coronary syndrome such as myocardial infarction heart attack, chronic liver disease, cerebral venous thrombosis, deep venous thrombosis or pulmonary embolism, arterial thrombosis, aneurysm, heart failure, ischemic heart diseases, angina pectoris, sudden cardiac death, hypertensive heart disease, non-coronary vessel disease, such as atherosclerosis, small vessel disease, vascular dementia, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema, chronic pulmonary disease, cardiomyopathies and a cardiovascular condition associated with an interventional procedure such as restenosis following angioplasty, placement of a stent, synthetic or neutral extension grafts; medical services featuring monoclonal antibodies, namely, conducting physical medical examinations in the fields of metabolic diseases including diabetes mellitus; preparation and dispensing of medications containing monoclonal antibodies; dietary and nutritional guidance featuring monoclonal antibodies; providing information of health care featuring monoclonal antibodies; consulting in the field of medicine, occupational therapy, and nutrition featuring monoclonal antibodies; veterinary services featuring monoclonal antibodies; beauty salons featuring monoclonal antibodies; animal sanitary services, namely, animal grooming services, animal health care, and veterinary services in the nature of euthanasia of animals featuring monoclonal antibodies; health care featuring monoclonal antibodies; consultancy and providing information in the fields of medical imaging, diagnostic properties of pharmaceuticals, and medical care related to human physiology and pathophysiology featuring monoclonal antibodies; pharmaceutical consultation featuring monoclonal antibodies; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals featuring monoclonal antibodies; physical performance monitoring in the nature of physical therapy or physiotherapy services featuring monoclonal antibodies; ergometry, namely, nutrition counseling featuring monoclonal antibodies; ergometry in the nature of health assessment, namely, blood tests featuring monoclonal antibodies for the evaluation of physical fitness or response to training
• GS0421: Testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs containing monoclonal antibodies; consultancy and providing information of testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs containing monoclonal antibodies; testing, inspection or research of medical treatment and technique containing monoclonal antibodies; research in the field of biotechnology and antibodies containing monoclonal antibodies; providing information of testing, inspection or research of medical treatment and technique containing monoclonal antibodies; scientific research of health care related to monoclonal antibodies; testing, inspection or research of biology related to monoclonal antibodies; computer software design, computer programming, or maintenance of computer software featuring monoclonal antibodies; computer hardware design and development related to monoclonal antibodies; computer software design and development related to monoclonal antibodies; consultancy and providing information in the field of development of pharmaceutical preparations containing monoclonal antibodies; consultancy and providing information in the field of biomedical research related to monoclonal antibodies

Case File Event Statements

• 8/19/2022 - 2 years ago

  66 - CANCELLED SEC. 8 (6-YR) Type: C8..

• 7/21/2021 - 3 years ago

  65 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 7/21/2021 - 3 years ago

  64 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR

• 7/21/2021 - 3 years ago

  63 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 7/21/2021 - 3 years ago

  62 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 2/9/2021 - 3 years ago

  61 - COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Type: REM1

• 5/13/2020 - 4 years ago

  60 - AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Type: ASGN

• 3/10/2016 - 8 years ago

  59 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 2/9/2016 - 8 years ago

  58 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 11/24/2015 - 9 years ago

  57 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 11/24/2015 - 9 years ago

  56 - PUBLISHED FOR OPPOSITION Type: PUBO

• 11/4/2015 - 9 years ago

  55 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 10/16/2015 - 9 years ago

  54 - NOA CANCELLED; REPUBLICATION REQUIRED Type: RPUB

• 10/16/2015 - 9 years ago

  53 - NOTICE OF ALLOWANCE CANCELLED Type: IUCN

• 10/15/2015 - 9 years ago

  52 - PETITION TO DIRECTOR - CHANGE BASIS - GRANTED Type: PCBG

• 10/14/2015 - 9 years ago

  51 - ASSIGNED TO PETITION STAFF Type: APET

• 10/9/2015 - 9 years ago

  50 - TEAS PETITION TO AMEND BASIS RECEIVED Type: TPAD

• 8/27/2015 - 9 years ago

  49 - REVIEW OF CORRESPONDENCE COMPLETE Type: CORV

• 4/23/2015 - 9 years ago

  48 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 4/21/2015 - 9 years ago

  47 - SOU EXTENSION 1 GRANTED Type: EX1G

• 4/21/2015 - 9 years ago

  46 - SOU EXTENSION 1 FILED Type: EXT1

• 4/21/2015 - 9 years ago

  45 - TEAS EXTENSION RECEIVED Type: EEXT

• 1/15/2015 - 10 years ago

  44 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU

• 11/19/2014 - 10 years ago

  43 - TEAS DELETE 1(B) BASIS RECEIVED Type: D1BR

• 10/28/2014 - 10 years ago

  42 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 9/2/2014 - 10 years ago

  41 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 9/2/2014 - 10 years ago

  40 - PUBLISHED FOR OPPOSITION Type: PUBO

• 8/13/2014 - 10 years ago

  39 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 7/31/2014 - 10 years ago

  38 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV

• 7/28/2014 - 10 years ago

  37 - EXPARTE APPEAL TERMINATED Type: EXPT

• 7/28/2014 - 10 years ago

  36 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 7/24/2014 - 10 years ago

  35 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 7/23/2014 - 10 years ago

  34 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 7/23/2014 - 10 years ago

  33 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 3/6/2014 - 10 years ago

  32 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 3/6/2014 - 10 years ago

  31 - NON-FINAL ACTION E-MAILED Type: GNRT

• 3/6/2014 - 10 years ago

  30 - NON-FINAL ACTION WRITTEN Type: CNRT

• 2/27/2014 - 10 years ago

  29 - PREVIOUS ALLOWANCE COUNT WITHDRAWN Type: ZZZX

• 2/10/2014 - 10 years ago

  28 - WITHDRAWN FROM PUB - OG REVIEW QUERY Type: PBCR

• 1/25/2014 - 11 years ago

  27 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV

• 1/23/2014 - 11 years ago

  26 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 1/23/2014 - 11 years ago

  25 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 1/23/2014 - 11 years ago

  24 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 1/23/2014 - 11 years ago

  23 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 1/23/2014 - 11 years ago

  22 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 1/6/2014 - 11 years ago

  21 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 1/6/2014 - 11 years ago

  20 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 12/30/2013 - 11 years ago

  19 - ASSIGNED TO LIE Type: ALIE

• 12/6/2013 - 11 years ago

  18 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR

• 12/6/2013 - 11 years ago

  17 - EX PARTE APPEAL-INSTITUTED Type: EXPI

• 12/6/2013 - 11 years ago

  16 - JURISDICTION RESTORED TO EXAMINING ATTORNEY Type: JURT

• 12/6/2013 - 11 years ago

  15 - EXPARTE APPEAL RECEIVED AT TTAB Type: EXAF

• 6/6/2013 - 11 years ago

  14 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN

• 6/6/2013 - 11 years ago

  13 - FINAL REFUSAL E-MAILED Type: GNFR

• 6/6/2013 - 11 years ago

  12 - FINAL REFUSAL WRITTEN Type: CNFR

• 5/16/2013 - 11 years ago

  11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 5/15/2013 - 11 years ago

  10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 5/15/2013 - 11 years ago

  9 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 11/16/2012 - 12 years ago

  8 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 11/16/2012 - 12 years ago

  7 - NON-FINAL ACTION E-MAILED Type: GNRT

• 11/16/2012 - 12 years ago

  6 - NON-FINAL ACTION WRITTEN Type: CNRT

• 11/15/2012 - 12 years ago

  5 - ASSIGNED TO EXAMINER Type: DOCK

• 8/13/2012 - 12 years ago

  4 - TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED Type: TAEA

• 8/13/2012 - 12 years ago

  3 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI

• 7/27/2012 - 12 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS

• 7/25/2012 - 12 years ago

  1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP